The search for a miRNA expression signature associated with patient outcome was first performed on a preliminary cohort of 13 primary neuroblastoma tumours whose risk at diagnosis was defined according to clinical criteria (age at diagnosis and stage) and MYCN amplification (Figure 1A). The gene discussed is MYCN; the disease is neuroblastoma.